Fenfluramine

ID: fenfluramine

Aliases: Fintepla

Type: compound

Route/form: oral or route depends on studied product

Status: approved_restricted_context

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, non-human/mechanistic, review/regulatory

Source types: human_rct, label, preclinical, review

Linked sources: 5

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• serotonin releasing agent
• sigma-1 receptor positive allosteric modulator

Optimization domains

• epilepsy
• serotonin
• sigma1

Research basis

• Fenfluramine is no longer just a withdrawn anorectic footnote: modern low-dose oral fenfluramine has label and randomized-trial support in Dravet syndrome seizure reduction.
• Sigma-1/allosteric literature explains why it appears in fringe neuro discussions, but the strongest human evidence is seizure-specific.
• Its history is useful for the repository because it shows how serotonergic weight-loss pharmacology can carry delayed cardiovascular liabilities.

Limits, risks, and missing evidence

• Historical valvulopathy and pulmonary-hypertension risk make casual metabolic or serotonergic use inappropriate.
• The modern label requires cardiac monitoring and is indication-specific; seizure-trial safety cannot be generalized to unsupervised performance use.
• Serotonergic interaction burden with SSRIs, TCAs, MAOIs, stimulants, and other monoaminergic drugs is high.

Risk flags

• approved drug
• restricted indication
• serotonergic
• valvulopathy pah monitoring
• interaction risk

Linked papers, labels, and reviews

1. Fenfluramine modulates anti-amnesic effects induced by sigma-1 receptor agonists
   preclinical / pubmed_fenfluramine_sigma1_2022
   Sigma-1 positive modulation context.
2. Allosteric modulators of sigma-1 receptor: a review
   review / pmc_sigma1_pam_review_2019
   Includes fenfluramine as a sigma-1 PAM.
3. DailyMed label: FINTEPLA fenfluramine oral solution
   label / dailymed_fintepla_label
   Official US label for fenfluramine oral solution; boxed/cardiac monitoring and serotonergic warnings anchor safety context.
4. Fenfluramine for treatment-resistant seizures in Dravet syndrome receiving stiripentol-inclusive regimens
   human_rct / pubmed_fenfluramine_dravet_rct_2019
   Randomized clinical trial in Dravet syndrome; relevant to the restricted modern fenfluramine use case.
5. Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo-controlled clinical trial
   human_rct / pubmed_fenfluramine_dravet_rct_2023
   Additional randomized placebo-controlled Dravet syndrome trial with echocardiographic safety monitoring.